Everything below concerns GLP-1 receptor agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-20. Numbers and descriptions here follow the published literature rather than marketing material.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
| Property | Value | Notes |
|---|---|---|
| Molecular class | 31-amino-acid peptide | Modified glucagon-like peptide-1 analogue |
| Molecular mass | approximately 4114 Da | Calculated for the free peptide backbone |
| Appearance | white to off-white powder | Typical of purified lyophilised peptide batches |
| Solubility class | freely soluble in water | Aqueous solubility improves at slightly alkaline pH |
| Typical storage | -20 degrees Celsius, dry, dark | Protect from repeated freeze-thaw cycles |
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
On 11 August, Lula and ministers unveiled a new Growth Acceleration Programme, according to the proposal, an estimated 1.7 trillion reais (worth around US$350 billion at the time) will be spent over the following 4 years. Of this, 610 billion is expected to be spent on slum urbanisation programmes, including the development of housing, public transport, sanitation, energy and protection from natural disasters, this includes further investments on social infrastructure programmes such as Minha Casa, Minha Vida, Luz Para Todos and Água Para Todos, as well as creation and expansion of ports, airports, motorways and railways. 540 billion is expected to be spent on expanding the electric grid and petrochemical industries, with 80% of the newly developed electric production capacity being expected to come from renewable sources; 349 billion is expected to be spent on transportation infrastructure, including for motor vehicles, trains, marine vehicles, and aeroplanes. Lula also announced the construction of the "West-East Integration Railway (FIOL)" as the first project of the programme, which will connect the southwest of Bahia to the coast of southern Bahia. Other areas of investment include "digital inclusion and connectivity" (expansion of 4G and 5G networks and digital education), healthcare (construction of new basic health units and maternities, as well purchase of ambulances and vaccines), education (construction, expansion and modernization of day care centers, full-time schools and federal institutes and universities) and defence infrastructure.
paucimannosylation, addition of simple glycans, primarily containing mannose and N-acetylglucosamine (GlcNAc), to asparagine residues O-GlcNAc, addition of N-acetylglucosamine to serine or threonine residues in a β-glycosidic linkage polysialylation, addition of polysialic acid (PSA) to neural cell adhesion molecule (NCAM) hydroxylation: addition of an oxygen atom to the side-chain of a Pro or Lys residue iodination: addition of an iodine atom to the aromatic ring of a tyrosine residue (e.g. in thyroglobulin) nucleotide addition such as ADP-ribosylation persulfidation, the addition of a sulfhydryl group onto a thiol group of a cysteine residue to form a hydropersulfide phosphate ester (O-linked) or phosphoramidate (N-linked) formation phosphorylation, the addition of a phosphate group, usually to serine, threonine, and tyrosine (O-linked), or histidine (N-linked) adenylylation, the addition of an adenylyl moiety, usually to tyrosine (O-linked), or histidine and lysine (N-linked) uridylylation, the addition of an uridylyl-group (i.e.
== Treaty of Shimonoseki == Per the terms of the Treaty of Shimonoseki, Japan was awarded the Liaodong Peninsula including the harbor city of Port Arthur, which it had conquered from China. Immediately after the terms of the treaty became public, Russia—with its own designs and sphere of influence in China—expressed concern about the Japanese acquisition of the Liaodong Peninsula and the possible impact of the terms of the treaty on the stability of China. Russia persuaded France and Germany to apply diplomatic pressure on Japan for the return of the territory to China in exchange for a larger indemnity.
Sources: en.wikipedia.org
Signs of sickle cell disease usually begin in early childhood. The severity of symptoms can vary from person to person, as can the frequency of crisis events. Sickle cell disease may lead to various acute and chronic complications, several of which have a high mortality rate.
Proteinogenic amino acids Cysteine (Cys, C) Methionine (Met or M), an essential amino acid in humans Metabolic products: Cystine, a cysteine dimer, and an oxidation product of cysteine Homocysteine (Hcy) Homocystine, a homocysteine dimer, and an oxidation product of homocysteine Cystathionine, produced by the transsulfuration pathway S-Adenosyl methionine (SAM, SAMe, SAM-e, AdoMet), a common cofactor in methyltransferases S-Adenosyl homocysteine (SAH), a side product of biomethylation by methyltransferases
The cost of the war to the United States was calculated by the US Congress in April 1992 to be $61.1 billion (equivalent to $122 billion in 2024). About $52 billion of that amount was paid by other countries. $36 billion by Kuwait, Saudi Arabia and other Arab states of the Persian Gulf. $16 billion were contributed by Germany and Japan, which sent no combat forces due to their constitutions. About 25% of Saudi Arabia's contribution was paid with in-kind services to the troops, such as food and transportation. US troops represented about 74% of the combined force, and the global cost was therefore higher.
=== Ka–Ke === Henrik Kacser FRSE (1918–1995). British geneticist and biochemist at Edinburgh, founder of metabolic control analysis. Emil T. Kaiser (1938–1988). Hungarian-born American protein chemist at the University of Chicago, known for his work on enzyme modification. Member Natl. Acad. Sci. USA. Herman Kalckar (1908–1991). Danish biochemist at the New York Public Health Research Institute, who worked on cellular respiration, nucleotide metabolism and galactose metabolism. Member Natl. Acad. Sci. USA Nathan O. Kaplan (1917–1986) Enzymologist at UC San Diego, founding editor of Methods in Enzymology. Member Natl. Acad. Sci. USA Sir Bernard Katz FRS (1911–2003). German-British neuroscientist and biophysicist at University College London. Nobel Prize in Physiology or Medicine (1970) for work on nerve biochemistry and the pineal gland. Stuart Alan Kauffman (b. 1939). American theoretical biologist, expert on complex systems, now at the University of Pennsylvania. Fellow of the Royal Society of Canada. Douglas Kell (b. 1953). British biochemist at the University of Manchester, known for research on functional genomics, metabolomics and the yeast genome. John Kendrew FRS (1917–1997). British x-ray crystallographer at the European Molecular Biology Laboratory, Heidelberg, known for determining the crystal structure of myoglobin. Nobel Prize in Chemistry (1962). Sir Ernest Kennaway FRS (1881–1958), British pathologist at the Institute of Cancer Research, London, who carried out early work on carcinogenic effects of hydrocarbons. Eugene P.
Sources: en.wikipedia.org
== Hybridization-based methods == Several applications have been developed that interrogate SNPs by hybridizing complementary DNA probes to the SNP site. The challenge of this approach is reducing cross-hybridization between the allele-specific probes. This challenge is generally overcome by manipulating the hybridization stringency conditions.
Kennedy Memorial Stadium, which would potentially allow the Commanders to move there in 2027, saying that the bill was "not in the best interest of the American taxpayer". After this bill passed Congress in December 2024, Moore and Washington Commanders owner Josh Harris signed a memorandum of understanding that the team would be responsible for developing the Northwest Stadium site if it moves to RFK Stadium. On April 28, 2025, Harris announced that the team would be building a New Stadium at RFK Campus to open in 2030. In May 2024, Moore signed into law a bill that would transfer ownership of the Pimlico Race Course to the Maryland Thoroughbred Racetrack Operating Authority, allowing for a state-funded, multi-million dollar renovation project of the race course's track to begin and for the construction of a new training center at a separate location. The bill would also consolidate thoroughbred racing in Maryland to Pimlico and have the Maryland state government assume responsibility over racing operations at the course by next year. In June 2026, the State of Maryland acquired the intellectual property rights of the Preakness Stakes after matching an $85 million offer made by Churchill Downs Incorporated.
the first was in Milan, Italy in 2015 addressing the issues of methodological harmonisation and traceability, the second in Mannheim, Germany to consider the impact of the digital revolution and its transformation for delivering services for patients.
Sources: en.wikipedia.org
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.
No. It shares high sequence identity but carries non-natural modifications that alter its stability and clearance. The naturally occurring hormone is broken down within minutes, while the synthetic analogue circulates far longer.
Attachment to serum albumin reduces renal filtration of the peptide and shields it from enzymatic breakdown. The consequence is a much longer interval between administrations than unmodified peptides allow. The precise contribution of binding affinity to overall duration is still being quantified.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and neutral endopeptidases. Semaglutide carries a non-natural amino acid at position eight that blocks that cleavage, and a fatty diacid side chain that binds albumin. The result is a much longer duration of action than the native hormone.